Evidence map›Paper›PMID 33929079›Full record

ArticlePharmacology research & perspectives2021

Effects of omecamtiv mecarbil on failing human ventricular trabeculae and interaction with (-)-noradrenaline.

Alexander Dashwood, Elizabeth Cheesman, Yee Weng Wong, Haris Haqqani, Nicole Beard, Karen Hay, Melanie Spratt, Wandy Chan, Peter Molenaar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. βNaunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Alexander DashwoodHeart Lung Institute, The Prince Charles Hospital, Chermside, QLD, Australia.ORCID 0000-0003-3693-4561
Elizabeth CheesmanCardio-Vascular Molecular & Therapeutics Translational Research Group, University of Queensland, Brisbane, QLD, Australia.ORCID 0000-0003-2230-1579
Yee Weng WongHeart Lung Institute, The Prince Charles Hospital, Chermside, QLD, Australia.ORCID 0000-0003-2645-154X
Haris HaqqaniHeart Lung Institute, The Prince Charles Hospital, Chermside, QLD, Australia.ORCID 0000-0003-1543-6686
Nicole BeardQueensland University of Technology, Brisbane, Australia.ORCID 0000-0002-8212-2209
Karen HayQIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.ORCID 0000-0001-8813-5855
Melanie SprattHeart Lung Institute, The Prince Charles Hospital, Chermside, QLD, Australia.
Wandy ChanHeart Lung Institute, The Prince Charles Hospital, Chermside, QLD, Australia.
Peter MolenaarHeart Lung Institute, The Prince Charles Hospital, Chermside, QLD, Australia.ORCID 0000-0002-7122-4656
The University of Queensland · AUQueensland University of Technology · AUQIMR Berghofer Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Omecamtiv mecarbil (OM) is a novel medicine for systolic heart failure, targeting myosin to enhance cardiomyocyte performance. To assist translation to clinical practice we investigated OMs effect on explanted human failing hearts, specifically; contractile dynamics, interaction with the β

Indexed as

Adrenergic alpha-AgonistsAdultAgedFemaleHeart FailureHeart VentriclesHumansMaleMiddle AgedMyocardial ContractionNorepinephrineUreaVentricular FunctionAdrenergic alpha-AgonistsNorepinephrineomecamtiv mecarbilUreaarrhythmiabeta-adrenoceptorcontractilitydiastoleheart failureinotropenoradrenalineomecamtiv mecarbilrelaxation

Identifiers

PMID33929079
PMCPMC8085933
OpenAlexW3159662851

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.